These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31618395)

  • 41. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
    Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of moderate exercise on Crohn's disease patients in remission.
    D'Incà R; Varnier M; Mestriner C; Martines D; D'Odorico A; Sturniolo GC
    Ital J Gastroenterol Hepatol; 1999 Apr; 31(3):205-10. PubMed ID: 10379481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease.
    Seeger WA; Thieringer J; Esters P; Allmendinger B; Stein J; Schulze H; Dignass A
    United European Gastroenterol J; 2020 Aug; 8(7):804-813. PubMed ID: 32580666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn's Disease.
    Shen W; Cao L; Li Y; Cai X; Ge Y; Zhu W
    Dis Colon Rectum; 2018 Jun; 61(6):706-712. PubMed ID: 29722729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
    Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
    Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
    Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in the management of Crohn's disease: economic and clinical potential of infliximab.
    Hanauer SB; Cohen RD; Becker RV; Larson LR; Vreeland MG
    Clin Ther; 1998; 20(5):1009-28. PubMed ID: 9829451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn's disease?
    Herman R; Sładek M; Pieczarkowski S; Dumnicka P; Fyderek K
    Folia Med Cracov; 2017; 57(2):63-71. PubMed ID: 29121038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Twenty years of biological therapy in an patient with IBD.
    Mak WY; Segal JP; Hart A
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
    Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.